Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
V Ambrosini, J Kunikowska, E Baudin, L Bodei… - European journal of …, 2021 - Elsevier
Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
Radioactive main group and rare earth metals for imaging and therapy
TI Kostelnik, C Orvig - Chemical reviews, 2018 - ACS Publications
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy
M Ljungberg, A Celler, MW Konijnenberg… - Journal of nuclear …, 2016 - Soc Nuclear Med
The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …
inception in 1925, has had as its principal objective the development of internationally …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European journal of …, 2022 - Springer
Abstract Purpose Radionuclide therapy with 177Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
A review of theranostics: perspectives on emerging approaches and clinical advancements
BJ Burkett, DJ Bartlett, PW McGarrah… - Radiology: Imaging …, 2023 - pubs.rsna.org
Theranostics is the combination of two approaches—diagnostics and therapeutics—applied
for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals …
for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals …
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
D Filosofov, E Kurakina, V Radchenko - Nuclear Medicine and Biology, 2021 - Elsevier
Abstract Targeted Auger Therapy represents great potential for the therapy of diseases
which require a high degree of selectivity on the cellular level (eg for therapy of metastatic …
which require a high degree of selectivity on the cellular level (eg for therapy of metastatic …
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning
M Cremonesi, ME Ferrari, L Bodei, C Chiesa… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y-labelled and 177 Lu-
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …